

DAFTAR PUSTAKA

- Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC; Levine B. 1999. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. *Genomics*, 59, pp.672–676.
- Abada, A. & Elazar, Z., 2014. Getting ready for building: signaling and autophagosome biogenesis. *EMBO Reports*, 15(8), pp.839–852.
- Abrams, B.J., Telford, W.G. & Rollins, L., 2014. The many roads to cell death: discriminating between apoptosis, necrosis and autophagy. *Cell Biology*, 15.
- Aghababazadeh, M. & Kerachian, M.A., 2014. Cell Fasting: Cellular Response and Application of Serum Starvation. *Journal of Fasting Health*, 2(4), pp.147–150.
- Akiko Kuma et al., 2004. The role of autophagy during the early neonatal starvation period. *Nature*, 432, pp.3–5.
- Altman, B.J. et al., 2011. Autophagy is Essential to Suppress Cell Stress and to Allow BCR-Abl-Mediated Leukemogenesis. , 30(16), pp.1855–1867.
- Arias, E. & Cuervo, A.M., 2012. Chaperone-mediated Autophagy in Protein Quality Control. *Curr Opin Cell Biol.*, 20(10), pp.1655–1662.
- Alalem, M., Ray, A. & Ray, B.K., 2016. Metformin induces degradation of mTOR protein in breast cancer cells. *Cancer Medicine*, 5(11), pp.3194–3206.
- Alalem, M., Ray, A. & Ray, B.K., 2016. Metformin Treatment Decreases mTOR mRNA Level in MCF-7 Breast Cancer Cells. , pp.99–109.
- American Cancer Society, 2015. *Breast Cancer Facts & Figures 2015-2016*, Atlanta.
- Anderson, W.F. et al., 2010. Male breast cancer: a population-based comparison with female breast cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 28(2), pp.232–9. Available at <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2815713&tool=pmcentrez&rendertype=abstract> [Accessed March 1, 2017].

- Apel, A. et al., 2008. Blocked Autophagy Sensitizes Resistant Carcinoma Cells to Radiation Therapy. *Cancer Research*, 68(5), pp.1485–1495.
- Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK and Elledge RM, 2004. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. *Clinical cancer research*, 10, pp.5670–5676.
- Austin, LK, Shensky K, Palazzo J, Avery T, Jaslow R, Ramos C, Hoke N, Petricoin E, Cristofanilli M., 2015 Identifying molecular targets and mechanisms of treatment resistance in Inflammatory Breast Cancer (IBC) using reverse-phase protein microarrays (RPMA). *Jefferson*, p.3.
- Azad, M., Chen, Y. & Gibson, G., 2009. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. *Antioxidants & Redox Signaling*, 11(4), pp.777–790
- Azim, H.A., Kassem, L. & Treilleux, I., 2016. Translational Oncology Analysis of PI3K / mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor– positive , HER2-negative Early Breast Cancer 1. *Translation Oncology*, 9(2), pp.114–123. Available at: <http://dx.doi.org/10.1016/j.tranon.2016.01.001>.
- Bachelot, T. et al., 2012. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer With Prior Exposure to Aromat. *Journal of Clinical Oncology*, 30(22), pp.2718–2724.
- Bakarakos, P. et al., 2010. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. *Histopathology*, 56, pp.876–882.
- Baselga, J. et al., 2012. Everolimus in postmeno- pausal hormone-receptor-positive advanced breast cancer. *NEngl J Med*, 366(6), pp.520–529.
- Beca, F. et al., 2017. p mTOR expression is associated with better prognosis in luminal breast carcinoma . *Journal of Clinical Pathology*, 67(11), pp.2–3.
- Berger, J. & Dice, J., 1985. Effect of serum deprivation and replacement on proteolysis in cultured human fibroblasts. *Prog. Clin. Biol. Res*, 180, pp.479–481.

- Booth, L.A. et al., 2014. The role of cell signalling in the crosstalk between autophagy and apoptosis. *Cellular Signalling*, 26(3), pp.549–555. Available at: <http://dx.doi.org/10.1016/j.cellsig.2013.11.028>.
- Bose S, Chandran S, Mirocha JM, B.N., 2006. The Akt pathway in human breast cancer: a tissue-array-based analysis. *Mod Pathol*, 19, pp.238–245.
- Brady, S.W. et al., 2015. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. *Cancer Biology and Therapy*, 16(3), pp.402–411
- Brunicardi, FC. et al., 2015. *Schwartz's Principles of Surgery* 10th ed., United States: McGraw-Hill Education.
- Brief, A., 2015. Assessing the Impact of Autophagy on Cellular Metabolism Real-Time , Functional Metabolic Assays Connect Energy Pathways and Autophagy Application Brief.
- Cairns, R.A., Harris, I.S. & Mak, T.W., 2011. Regulation of cancer cell metabolism. *Nature Reviews Cancer*, 11. Available at: <http://dx.doi.org/10.1038/nrc2981>.
- Caro-Maldonado, A. & Muñoz-Pinedo, C., 2011. Dying for Something to Eat: How Cells Respond to Starvation. *Open Cell Signaling J*, 3, pp.42–51.
- Chaabane, W. et al., 2013. Autophagy , Apoptosis , Mitoptosis and Necrosis : Interdependence Between Those Pathways and Effects on Cancer. , pp.43–58.
- Chen, R. et al., 2014. The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation. *The Journal of Cell Biology*, 206(2), pp.173–182. Available at: www.jcb.org/cgi/doi/10.1083/jcb.201403009
- Cancer Research UK, 2017. No Title. Available at: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>.
- Chiang, G.G. & Abraham, R.T., 2007. Targeting the mTOR signaling network in cancer. *Trends Mol Med*, 13(10), pp.433–442.
- Choi, A.M.K., Ryter, S.W. & Levine, B., 2013. Autophagy in Human Health and Disease. *The New England Journal of Medicine*, 368(7), pp.651–662.

- Chaabane, W; User SD;E-Gazzah M; Jaksik R; Sajjadi E, Rzeszowska-Wolny J; Los MJ. 2013. Autophagy , Apoptosis , Mitoptosis and Necrosis : Interdependence Between Those Pathways and Effects on Cancer. , pp.43–58.
- Choi, A.M.K., Ryter, S.W. & Levine, B., 2013. Autophagy in Human Health and Disease. , pp.651–662.
- Chen L, Liu D, Zhang Y, Zhang H. and Cheng H., 2015. The autophagy molecule Beclin 1 maintains persistent activity of NF-kappaB and Stat3 in HTLV-1-transformed T lymphocytes. *Biochemical and biophysical research communications*, 465, pp.739–745.
- Clarke R & Katherine C. 2015, Unfolding the Role of Stress Response Signaling in Endocrine Resistance Breast Cancer. *Frontiers in Oncology*. 5. 140.10.3389/fonc.2015.00140
- Creighton, C.J., 2007. A gene transcription signature of the Akt / mTOR pathway in clinical breast tumors. *Oncogene*, (26), pp.4648–4655.
- Cuervo, A.M., 2009. Autophagy and aging. *Trends Genet*, 24(12), pp.604–612.
- Cuervo, A.M. & Macian, F., 2014. Autophagy, nutrition and imm. *Molecular Aspects Medicine*, 33(1), pp.2–13.
- Dey, N., De, P. & Leyland-jones, B., 2017. Pharmacology & Therapeutics PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. *Pharmacology and Therapeutics*. Available at: <http://dx.doi.org/10.1016/j.pharmthera.2017.02.037>.
- Dey, N., De, P. & Leyland-Jones, B., 2016. PI3K-mTOR in cancer and cancer therapy. In B. A. Teicher (Ed.), *Cancer drug discovery and Development PI3K-mTOR in cancer and cancer therapy*. AG Switzerland: Springer International Publishing.
- Ding, X. et al., 2017. P-mTOR Expression and Implication in Breast Carcinoma : A Systematic Review and Meta- Analysis. *PLoS ONE*, 12(1), pp.1–16.
- Dowling, R.J. et al., 2010. Dissecting the role of mTOR: Lessons from mTOR inhibitors. *Biochimica et Biophysica Acta*, 1804, pp.433–439.
- Dong M, Wan XB, Yuan ZY, Wei L, Fan XJ, Wang TT, Lv YC, Li X, Chen ZH, Chen J, Lin Q, Wen JY, Ma XK, Liu Q. and Wu XY., 2013. Low expression of Beclin 1 and elevated expression of HIF-1alpha refine

distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. *Medical oncology*, 30, p.355.

Droog, M. et al., 2013. Tamoxifen resistance: From bench to bedside. *Eur J Pharmacol*, 717(1), pp.47–57.

Desantis, C.E. et al., 2016. Cancer Statistics for African Americans , 2016 : Progress and Opportunities in Reducing Racial Disparities.

Desantis, C.E. et al., 2014. Cancer Treatment and Survivorship Statistics , 2014. *CA: A Cancer Journal for Clinicians*, 64(4), pp.252–271.

Dillon, R. L., Marcotte, R., Hennessey, B. T., Woodgett, J. R., Mills, G. B., and Muller, W.J., 2009. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer Research*, 69, pp.5057–5064.

Degenhardt, K. et al., 2006. Autophagy promotes tumor cell survival and restricts necrosis , inflammation , and tumorigenesis. , (July), pp.51–64.

Deter, R.L., Baudhuin, P. & Duve, C.D.E., PARTICIPATION OF LYSOSOMES IN CELLULAR AUTOPHAGY INDUCED IN RAT LIVER BY GLUCAGON. *Communications*, (7).

Dice, J.F., 2017. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. *Cell Press*, 15(8), pp.1–2. Available at: [https://doi.org/10.1016/0968?0004\(90\)90019?8](https://doi.org/10.1016/0968?0004(90)90019?8) Get.

Duden, R. et al., 2003. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant Huntingtin exon 1 by ... Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR pho. *Research Gate*, (May 2017).

Dunlop, E.A. et al., 2011. ULK1 inhibits mTORC1 signaling , promotes multisite Raptor phosphorylation and hinders substrate binding. *Autophagy*, 7(7), pp.737–747.

Dyke, R.W. Van, 1988. Proton Pump-generated Electrochemical Gradients in Rat Liver Multivesicular Bodies. *The Journal of Biological Chemistry*, 263(6), pp.2603–2611.

Ebato, C. et al., 2008. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat die. *Cell Metab*, 8, pp.325–332.

- Edinger, A.L. & Thompson, C.B., 2004. Death by design : apoptosis , necrosis and autophagy. *Current Cancer Research*, 16, pp.663–669.
- Edinger, A.L. & Thompson, C.B., 2003. Defective autophagy leads to cancer. *Cancer Cell*, 4(6), pp.422–424. Available at: [http://dx.doi.org/10.1016/S1535-6108\(03\)00306-4](http://dx.doi.org/10.1016/S1535-6108(03)00306-4).
- Egan, D.F. et al., 2011. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science*, 331(6016), pp.456–461.
- Eng, C.H. et al., 2017. Ammonia Derived from Glutaminolysis Is a Diffusible Regulator of Autophagy. *Cell Biology*, 3(119), pp.1–7.
- Eng, C.H. & Abraham, R.T., 2010. Glutaminolysis yields a metabolic by-product that stimulates autophagy. *Autophagy*, 6(7), pp.968–970.
- Funderburk SF, Wang QJ, Yue Z., 2010. The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. *Trends in cell biology*, 20, pp.355–362.
- Furuya N, Yu J, Byfield M, Pattingre S, Levine B., 2005. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. *Autophagy*, 1(1), pp.46–52.
- Finn, P. & Dice, J., 2005. Ketone bodies stimulate chaperone-mediated autophagy. *J. Biol. Chem*, 280, pp.25864–25870.
- Fuertes, G. et al., 2003. Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal , amino-acid deprivation. *Biochemistry*, 375, pp.75–86.
- GLOBOCAN, 2012. *All Cancers (excluding non melanoma skin cancer) Estimated Incidence , Mortality and Prevalence Worldwide in 2012 Estimated Cancer Incidence Worldwide in 2012 : Men*,
- Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V, Tharinger H, Delbos L, Gary-Gouy H, Morel AP, Ghavami S, Song E, Codogno P, Mehrpour M, 2013. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. *Oncogene*, 32, pp.2261–2272.
- Gu, Y; Chen T, Li G; Xu C; Xu Z; Zhang J; He K; Zheng L; Guan Z; Su X; Cao J Teng L, 2016. Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. *Oncotarget*.

- Ganley, I.G. et al., 2009. ULK1 * ATG13 * FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy *. *Journal Of Biological Chemistry*, 284(18), pp.12297–12305.
- George N. Naumov, Folkman, J. & Oddbjorn Straume, 2009. Tumor dormancy due to failure of angiogenesis : role of the microenvironment. *Clinical & Experimental Metastasis*, 26(1), pp.1–19. Available at: <https://rd.springer.com/article/10.1007%2Fs10585?008?9176?0>.
- Gozuacik, D. & Kimchi, A., 2004. Autophagy as a cell death and tumor suppressor mechanism. *Oncogene*, 23, pp.2891–2906.
- Green, D., Galluzzi, L. & G, G.K., 2014. Metabolic control of cell death. *Science*, 345, pp.125–156.
- Guo, J.Y. et al., 2011. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes and Development*, 25, pp.460–470. Available at: <http://www.genesdev.org/cgi/doi/10.1101/gad.2016311>.
- Haft BG et al., 2006. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. *Journal of Medical Genetics*, 43(2), pp.133–137.
- He C. and Levine B., 2010. The Beclin 1 interactome. *Current opinion in cell biology*, 22, pp.140–149.
- He, C. et al., 2012. Exercise induced BCL2 regulated autophagy is required for muscle glucose homeostasis. *Nature*, 481, pp.511–515.
- He, C. & Klionsky, D.J., 2010. Regulation Mecanism and Signaling Pathways of Autophagy. *Annu Rev Genet*, 43(68), pp.67–93.
- Huang, W. & Klionsky, D.J., 2002. Autophagy in Yeast: A Review of the Molecular Machinery Autophagy and related vacuolar trafficking pathways. *Cell Structure and Function*, 27, pp.409–420.
- Howdaler, N. et al., 2015. SEER Cancer Statistics Review, 1975-2013. *National Cancer Institute*. Available at: http://seer.cancer.gov/csr/1975_2013
- Hare, S.H. & Harvey, A.J., 2017. mTOR Function and Therapeutic Targeting in Breast Cancer. *Am J Cancer Res*. 2017 Mar 1;7(3):383-404 ecollection 2017

- Hu, A. et al., 2014. Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma. *Tumori*, (100), pp.541–546.
- International Agency for Research on Cancer (IARC) / WHO, 2012. Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx [Accessed February 28, 2017].
- Iqbal, Nida & Iqbal, Naveed, 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers : Overexpression and Therapeutic Implications. *Molecular Biology International*, 2014, pp.1–9.
- Ito, Y. et al., 2015. Everolimus plus exemestane in post- menopausal patients with estrogen-receptor-positive advanced breast cancer— Japanese subgroup analysis of BOLERO-2. *Gan to kagaku ryoho Cancer & chemotherapy*, 42(1), pp.67–75.
- Jemal, A., Bray, F. & Ferlay, J., 2011. Global Cancer Statistics. *CA Cancer J Clin* 2011, 61(2), pp.69–90. Karar, J. & Maity, A., 2011. PI3K/AKT/mTOR pathway in angiogenesis. *Frontiers in Molecular Neuroscience*, 4(December), pp.1–8.
- John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T. and Thomas TJ., 2008. Regulation of estrogenic effects by beclin 1 in breast cancer cells. *Cancer Research*, 68, pp.7855–7863.
- Jung, C.H. et al., 2011. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. *Autophagy*, 7(10), pp.1212–1221.
- Kanazawa, T. et al., 2004. Amino Acids and Insulin Control Autophagic Proteolysis through Different Signaling Pathways in Relation to mTOR in Isolated Rat Hepatocytes *. *The Journal of Biological Chemistry* 279(9), pp.8452–8459.
- Karvela, M. et al., 2017. ATG7 regulates energy metabolism , differentiation and survival of Philadelphia-chromosome-positive cells. *Autophagy*, 12(6), pp.936–948. Available at: <http://dx.doi.org/10.1080/15548627.2016.1162359>.
- Kaushik, S. et al., 2011. Autophagy in hypothalamic AgRP neuros regulates food intake and energy balance. *Cell. Metab.*
- Keyvani, V. & Kerachian, M., 2014. The Effect of Fasting on the Important Molecular Mechanisms Related to Cancer Treatment. *J Fasting Health*, 2(3), p.113.

- Kiffin, R. et al., 2004. Activation of Chaperone-mediated Autophagy during Oxidative Stress □. *Molecular Biology of the Cell*, 15(November), pp.4829–4840.
- Kim, K.M. & Sang Geon Kim, 2014. Autophagy and microRNA dysregulation in liver diseases. *Archives of Pharmacal Research*, 37(9), pp.1097–1116.
- Klionsky, D.J. & Emr, S.D., 2009. Autophagy as a Regulated Pathway of Cellular Degradation. *Science*, 290(5497), pp.1717–1721.
- Koga, H., Kaushik, S. & Cuervo, A.M., 2010. Altered lipid content inhibits autophagic vesicular fusion. *The Journal of the Federation of American Societies for Experimental Biology*, 24(8), pp.3052–3065.
- Komatsu, M. et al., 2005. Impairment of starvation-induced and constitutive autophagy in. *The Journal of Cell Biology*, 169(3), pp.425–434.
- Kementerian Kesehatan RI, 2015. *Cancer Profile-Yayasan Kanker Indonesia*, Available at:
http://kanker.kemkes.go.id/yki_read.php?id=3.
- Kementerian Kesehatan RI, 2016. *InfoDATIN: Bulan Peduli Kanker Payudara*, Jakarta.
- Kondo Y, Kanzawa T, Sawaya R, Kondo S., 2005. The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer*, 5(9), pp.726–734.
- Korski K, Malicka A, and P.W., 2017. The Expression of Phosphorylated mTOR in Breast Cancer from BRCA1 Mutation. *Cancer Research*, 69(24 Supplement), pp.2–3.
- Kotoulas, O.B.Ã., Kalamidas, S.A. & Kondomerkos, D.J., 2006. Glycogen autophagy in glucose homeostasis. *Pathology Research And Practice*, 202, pp.631–638.
- Kroemer, G., Mariño, G. & Levine, B., 2011. Autophagy and the integrated stress response. *Mol Cell*, 40(2), pp.280–293.
- Lagadec, C. et al., 2013. Radiation-induced reprogramming of breast cancer cells. *Stem Cells*, 30(5), pp.833–844.
- Lai, C. et al., 2014. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. *Oncotarget*, 5(14), pp.5523–5534.

- Lai, Y. et al., 2017. of Molecular Medicine. *International Journal of Molecular Medicine*, 37(2), pp.1–12.
- Lehmann, B.D. et al., 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *The Journal of Clinical Investigation*.
- Lei, Y. et al., 2017. Metformin targets multiple signaling pathways in cancer. *Chinese Journal of Cancer*, 36(17), pp.1–9.
- Li, Z., Chen, B., Wu, Y., Jin, F., Xia, Y., and Liu, X., 2010. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. *BMC Cancer*, 10, p.98.
- Liang LZ, Ma B, Liang YJ, Liu HC, Zheng GS, Zhang TH, Chu M, Xu PP, Su Y. and Liao G., 2012. High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. *Journal of oral pathology & medicine*, (41), pp.621–629.
- Liang XH; Jackson S; Seaman M, Brown K; Kempkes B, 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature*, 402(6762), pp.672–676.
- Liu, H. et al., 2012. Metformin and the mTOR Inhibitor Everolimus (RAD001) Sensitize Breast Cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro. *Anticancer Research*, (32), pp.1627–1638.
- Lo, S. & Hsueh, C., 2012. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. *Int J Clin Exp Pathol*, 5(8), pp.806–813.
- Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., and Debnath, J., 2011. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. *Molecular Biology of the Cell*, 22, pp.165–178.
- Lane, J., Wilkinson, S. & Cecconi, F., 2017. Autophagy and the Cell Cycle : A Complex Landscape. *Frontiers in Oncology*, 7(March), pp.1–16.
- Liu, H., He, Z. & Simon, H., 2015. Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis. *J Mol Med*, 93, pp.159–164.
- Lozya, F. & Karantza, V., 2013. NIH Public Access. *Semin Cell Dev Biol*, 23(4), pp.395–401.

- Lum, J.J. et al., 2005. Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis. *Cell*, 120, pp.237–248.
- Lytvyn, D.I. et al., 2017. -tubulin acetylation and detyrosination correlate with starvation-induced autophagy in tobacco cells. Available at: <http://dx.doi.org/10.1101/111484>.
- Margariti, N. et al., 2010. “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future? *Breast Cancer Research and Treatment*, 128(3), pp.599–606.
- Matsunaga, K., Saitoh, T., Tabata, K., Omori, H., Satoh, T., Kurotori, N., Maejima, I., Shirahama-Noda, K., Ichimura, T., Isobe, T., Akira, S., Noda, T., and Yoshimori, T., 2009. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. *Nature Publishing Group*, 11, pp.385–396.
- Matsunaga, K., Morita, E., Saitoh, T., Akira, S., Ktistakis, N. T., Izumi, T., Noda, T., and Yoshimori, T., 2010. Autophagy requires endoplasmic reticulum targeting of the PI3-kinase complex via Atg14L. *The Journal of Cell Biology*, 190, pp.511–521.
- Maycotte, P. & Thorburn, A., 2014. WJCO. *World Journal of Clinical Oncology*, 5(3), pp.224–241
- McAuliffe, P. et al., 2010. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. *Clin Breast Cancer*, 10, pp.S59–65.
- Miller, K.D. et al., 2016. Cancer Treatment and Survivorship Statistics , 2016. CA: A Cancer Journal for Clinicians, 66(4), pp.271–289.
- Miller, T.W. et al., 2009. Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells. *Clinical Cancer Research*, 15(23), pp.7266–7277.
- Miller, T.W. et al., 2010. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor – positive human breast cancer. *The Journal of Clinical Investigation*, 120(7), pp.2406–2413.
- Mimoto, R. et al., 2017. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. *Cancer Letters*, 384, pp.27–38. Available at: <http://dx.doi.org/10.1016/j.canlet.2016.10.015>.

- Morandi, A., and Chiarugi, P., 2014. Metabolic implication of tumor:stroma crosstalk in breast cancer. *J. Mol. Med*, 92, pp.117–126.
- Mutee, A. et al., 2009. Immunohistochemical expression of mTOR protein in breast carcinoma tissues. *The Internet Journal of Laboratory Medicine*, 4(1), pp.1–11.
- AF, Kaur G, Kumar G, Muhammad TST, Khalid IA, Tan ML, 2009. Immunohistochemical Evaluation of mTOR and Beclin-1 Protein Expression in Human Breast Cancer and Adjacent Normal Tissues , A Study in Malaysian Patients. *The Open Pathology Journal*, 3, pp.111–117
- Mack, H.I.D. et al., 2012. AMPK-dependent phosphorylation of ULK1 regulates ATG9 localization. *Autophagy*, 8(8), pp.1197–1214.
- Martinez-outschoorn, U.E. et al., 2011. Cancer cells metabolically “ fertilize ” the tumor microenvironment with hydrogen peroxide , driving the Warburg effect Implications for PET imaging of human tumors. *Cell Cycle*, 10(15), pp.2504–2520.
- Martinez-outschoorn, U.E. et al., 2010. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution A new paradigm for understanding tumor metabolism , the field effect and genomic instability in cancer cells. *Cell Cycle*, 9(16), pp.3256–3276.
- Mbeunkui, F. & Jr, D.J.J., 2010. Cancer and the tumor microenvironment: a review of an essential relationship. *Cancer Chemother Pharmacol*, 63(4), pp.571–582.
- Mehrpour, M. et al., 2010. Overview of macroautophagy regulation in mammalian cells. *Nature Publishing Group*, 20(7), pp.748–762. Available at: <http://dx.doi.org/10.1038/cr.2010.82>.
- Mizushima, N. et al., 2009. Autophagy fights disease through cellular self-digestion. *Nature*, 451(7182), pp.1069–1075.
- Mizushima, N., Yoshimori, T. & Ohsumi, Y., 2011. The role of Atg proteins in autophagosome formation. *Annu Rev Cell Dev*, 27, pp.107–132.
- Mortimore, G. & Mondon, C., 1970. Inhibition by insulin of valine turnover in liver. *J. Biol. Chem*, 245, pp.2375–2383.
- Mortimore, G.E. & Poso, A.R., 1987. Catabolism and its control during nutrient deprivation and supply Classes of Breakdown. *Ann. Rev. Nutr.*, 7, pp.539–564.

- Nagelkerke, A. et al., 2015. Therapeutic targeting of autophagy in cancer. Part II: pharmacological modulation of treatment-induced autophagy. *Semin Cancer Biol*, 31, pp.99–105.
- Negri T, Tarantino E, Orsenigo M, Reid JF, Gariboldi M, Zambetti M, Pierotti MA and Pilotti S., 2010. Chromosome band 17q21 in breast cancer: significant association between Beclin 1 loss and HER2/NEU amplification. *Genes Chromosomes Cancer*, 49, pp.901–909.
- Nicotra G, Mercalli F, Peracchio C, Castino R, Follo C, Valente G. and Isidoro C., 2010. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. *Modern pathology*, (23), pp.297–8950.
- Nicklin, P. et al., 2013. Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy. *Cell*, 136(3), pp.521–534.
- Panda, P. et al., 2015. Mechanism of autophagic regulation in carcinogenesis and cancer therapeutics. *Semin Cell Dev Biol*, 39, pp.43–55.
- Paplomata, E. & Regan, R.O., 2014. The PI3K / AKT / mTOR pathway in breast cancer : targets , trials and biomarkers. , pp.154–166.
- Proikas-Cezanne T & Codogno P, 2011. Beclin 1 or not Beclin 1. *Autophagy*, 7, pp.671–672. Rikiishi, H., 2012. Novel Insights into the Interplay between Apoptosis and Autophagy. *International Journal of Cell Biology*, 2012(317645), pp.1–15.
- Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G. and Levine B., 2003. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *The Journal of clinical investigation*, (112), pp.1809–1820.
- Raben, N. et al., 2010. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder — murine Pompe disease. *Autophagy*, 6(8), pp.1078–1089.
- Rabinowitz, J.D. & White, E., 2010. Autophagy and Metabolism. *Science*, (December 2010), pp.1–5.
- Reid, M.A. et al., 2013. Article The B55 a Subunit of PP2A Drives a p53-Dependent Metabolic Adaptation to Glutamine Deprivation. *Molecular Cell*, 50(2), pp.200–211. Available at: <http://dx.doi.org/10.1016/j.molcel.2013.02.008>.

- Russell, R.C., Yuan, H. & Guan, K., 2013. Autophagy regulation by nutrient signaling. *Nature Publishing Group*, 24(1), pp.42–57. Available at: <http://dx.doi.org/10.1038/cr.2013.166>.
- Rohatgi, R.A., Janusis J, Leonard D, Bellvé KD, Fogarty KE, Baehrecke EH, Corvera S, Shaw LM. Beclin 1 regulates growth factor receptor signaling in breast cancer. *Oncogene*, 34(42), pp.5352–5362.
- Rohatgi, R.A. Shaw LM., 2016. An autophagy-independent function of Beclin 1 in cancer. *Molecular and Cellular Oncology*, 3556, pp.1–4.
- Sahu, R. et al., 2012. Microautophagy of cytosolic proteins. *Dev Cell*, 20(1), pp.131–139.
- Sarkar, S. et al., 2007. Trehalose , a Novel mTOR-independent Autophagy Enhancer , Accelerates the Clearance of Mutant Huntingtin. *THE JOURNAL OF BIOLOGICAL CHEMISTRY*, 282(8), pp.5641–5652.
- Schworer, C., Cox, J. & Mortimore, G., 1979. Alteration of lysosomal density by sequestered glycogen during deprivation-induced autophagy in rat liver. *Biochem. Biophys. Res. Commun*, 87, pp.163–170.
- Shintania, T. et al., 2010. Glucosamine induces autophagy via an mTOR-independent pathway. *Biochemical and biophysical research communications*, 391(4), pp.1775–1779. Available at: <https://doi.org/10.1016/j.bbrc.2009.12.154>.
- Singh, R. et al., 2010. Autophagy regulates lipid metabolism. *Nature*, 458(7242), pp.1131–1135.
- Singh, R. & Cuervo, A.M., 2011. Review Autophagy in the Cellular Energetic Balance. *Cell Metabolism*, 13(5), pp.495–504. Available at: <http://dx.doi.org/10.1016/j.cmet.2011.04.004>.
- Shi CS & Kehrl JH, 2008. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. *The Journal of biological chemistry*, 283, pp.33175–33182.
- Siegel, R.L., Miller, K.D. & Jemal, A., 2017. Cancer Statistics , 2017. *CA Cancer J Clin* 2017, 67(1), pp.7–30.
- Thomas S, Thurn KT, Biçaku E, Marchion DC.and Münster PN, 2011. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. *Breast Cancer Res Treat*, 130, pp.437–447.

- Thoresen, S.B, Pedersen, N.M., Liestøl, K, Stenmark, H., 2010. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. *Experimental Cell Research*, 316(3368-3378).
- Tomasetti, M. et al., 2015. MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma. *Oncotarget*, 7(24), pp.36338–36352. Available at: www.impactjournals.com/oncotarget.
- Townsend C, JR., M. et al., 2012. *Sabiston textbook of surgery: the biological basis of modern surgical practice* 19th ed., Canada: Elsevier Inc.
- Ueng, S. et al., 2012. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. , 5(8), pp.806–813.
- Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M, 2016. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. *BMC Cancer*, 16(230), pp.1–9.
- Urasaki, Y., Heath, L. & Xu, C.W., 2012. Coupling of Glucose Deprivation with Impaired Histone H2B Monoubiquitination in Tumors. *PLoS ONE*, 7(5), pp.1–5.
- Vabulas, R.M. & Hartl, F.U., 2005. Protein Synthesis upon Acute Nutrient Restriction Relies on Proteasome Function The mechanisms that protect mammalian cells against amino acid deprivation are only. *Science*, 310(5756), pp.1–6.
- Vazquez-martin, A., Oliveras-ferraros, C. & Barco, S. Del, 2011. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. *Breast Cancer Res Treat*, 126(2), pp.355–364.
- Vicier, C. et al., 2014. Clinical development of mTOR inhibitors in breast cancer. , 16(1), pp.1–9.
- Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, 2012. mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors. *The Breast*, 21(2), pp.178–182.

- Wang MC, Wu AG, Huang YZ, Shao GL, Ji SF, Wang RW, Yuan HJ, Fan XL, Zheng LH, Jiao QL, 2015. Autophagic regulation of cell growth by altered expression of Beclin 1 in triple-negative breast cancer. *International Journal f Exp Med*, 8(5), pp.7049–7058.
- Wang, K. *et al.*, 2016. Comparison of Clinicopathological Features and Treatments between Young (40Years) and Older (>40Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, CaseOnlyStudy. *PLoS ONE*.
- Wazir, U. *et al.*, 2013. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer. *Oncology Reports*, (29), pp.1969–1974.
- Wellen, K.E. & Craig, B., 2012. A two way street : reciprocal regulation of metabolism and signalling. *Nature Reviews Molecular Cell Biology*, 13, pp.270–276.
- Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G. and Levine .B., 2013. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell*, 154, pp.1269–1284
- White, E., 2013. Deconvoluting the context-dependent role for autophagy in cancer. *Nat Rev Cancer*, 12(6), pp.401–410.
- Wirawan, E., Lippens, S., Vanden Berghe, T., Romagnoli, A., Fimia, G. M., Piacentini, M., and Vandenabeele, P., 2012. Beclin1: A role in membrane dynamics and beyond. *Autophagy*, 8, pp.6–17.
- Wouters, B.G. & Koritzinsky, M., 2008. Hypoxia signalling through mTOR and the unfolded protein response in cancer. *Nat Rev Cancer*, 8, pp.851–864.
- Wu, S. *et al.*, 2016. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK / mTOR pathway. *Journal of Biomedical Science*, 23(60), pp.1–10. Available at: <http://dx.doi.org/10.1186/s12929-016-0275-y>.
- Wu, V.S. *et al.*, 2016. From bench to bedside: what do we know about Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-positive breast cancer? *J Steroid Biochem Mol Biol*, (153), pp.45–53.
- Xu, K., Liu, P. & Wei, W., 2014. mTOR signaling in tumorigenesis. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1846(2), pp.638–654.

- Yamamoto, A., Cremona, M.L. & Rothman, J.E., 2006. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. *The Journal of Cell Biology*, 172(5), pp.719–731.
- Yeh, E.S., Abt, M.A. & Hill, E.G., 2015. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. *Breast Cancer Research and Treatment*, (149), pp.91–98.
- Yue Z, Jin S, Yang C, Levine AJ. and Heintz N., 2003. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proceedings of the National Academy of Sciences of the United States of America*, (100), pp.15077–15082.
- Zhineng J. Yang et al., 2012. The Role of Autophagy in Cancer : Therapeutic Implications. *Mol Cancer Ther*, 10(9), pp.1533–1541.
- Zhou, X. et al., 2004. Activation of the Akt / Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. , 10, pp.6779–6788.
- Zhou, Y., Rucker E.B. & Zhou, B.P., 2016. Autophagy regulation in the development and treatment of breast cancer. , 48(December 2015), pp.60–74.
- Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, Ding YG, Wan XB, Guan Z, Li HG, Lin DJ, Shao CK. and Liu Q., 2012. Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer. *Autophagy*, (8), pp.389–400.